Participants with a qualifying genetic diagnosis in the DECIPHER database.
01 — The cohort
The study begins after the diagnostic odyssey
These were not children screened from the general population. They had severe, previously undiagnosed developmental disorders and a pathogenic or likely pathogenic result through the Deciphering Developmental Disorders study.
Clinical notes were reviewed for 85% of those eligible across all 24 recruiting services.
Treatment, testing or screening changed after the diagnosis: 27.9% of recorded outcomes.
3.4 yearsMedian time from study recruitment to a result. The participant was a median 11 years old when the result arrived.
Counts are diagnosed DDD probands, not population screening results. Outcome data were collected from clinical genetics notes between March 2021 and July 2022.
02 — The clinical effect
A result changed medical management for about one in four
A genetic result did not rewrite every care plan. But for 1,183 children, clinicians recorded a treatment, test or screening decision that changed because a molecular diagnosis was available.
One hundred diagnosed children
Dots filled in blue represent the 27.9% with a recorded clinical management change.
The number is consequential, but not universal. Rates varied from 11% to 52% across the 24 regional genetics services. The researchers say workforce capacity, referral practice and variation in clinical records may contribute to that spread.
10%
For 418 children, clinicians reported that an earlier diagnosis might have avoided interventions such as MRI scans or muscle biopsies.
Clinical management includes treatment, testing or screening started, stopped, avoided or reviewed. It excludes support groups, educational services and reproductive testing.
03 — What changed
Surveillance, not a prescription, was the main clinical effect
The diagnosis most often prompted clinicians to look for known complications. Disease-specific treatment was much rarer. These outcomes overlap: one child could receive more than one action.
MonitoringTreatmentAvoided testingAvoided medicine
The visual scale runs to 30%, so small but nonzero outcomes remain visible. Counts: 903 children started tests or screening; 85 started disease-specific treatment; 26 stopped or avoided testing; 20 stopped or avoided medication.
04 — Where care moved
The genetic answer opened doors across the hospital
When new testing or surveillance began, referrals were distributed across specialties. Cardiology alone accounted for more than a quarter of the 1,334 recorded referral episodes.
Top eight destinations shown. Remaining episodes included audiology, dentistry, dermatology, orthopaedics and other specialties. Percent shares in the study use referral episodes as the denominator.
05 — Beyond the child’s chart
The result also changed what families could know and plan
The most common recorded outcome was not a medical procedure. It was access to condition-specific information or support—a way to replace an unnamed problem with a shared body of knowledge.
3,214 families; this could include patient information or scientific literature.
1,222 families had at least one reproductive testing option discussed.
880 families were involved in groups organized around a condition or rare disorder.
Family outcomes can overlap. The study reviewed what was recorded in genetics notes; it did not survey families directly about wellbeing, education, finances or social support.
06 — What the result means
A diagnosis is a map, not a cure
The value in this cohort was mostly directional: surveillance for known risks, fewer unnecessary investigations, a name families could research and choices they could discuss. That is meaningful without pretending it resolves the disorder.
What it can change
Testing, specialist surveillance, selected treatments, reproductive discussions and access to condition-specific information.
What it rarely changed here
Only 2% started a disease-specific treatment. Molecularly targeted treatments for monogenic developmental disorders remained limited.
What this study cannot tell us
It cannot measure population benefit, causality or family-reported quality of life. It covers a selected cohort with severe, previously undiagnosed disorders.
The result mattered most when it changed the next question from What is happening? to What should we watch, avoid or plan now?